Science Updates

Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer — Final Results From HERIZON-BTC-01

mRNA-Based COVID Vaccines May Generate Improved Responses to Immunotherapy

Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher

First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF)

Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC Who Progressed on CDK4/6 Inhibitors

Exceptional Response to Single-Agent Anti-PD1 Therapy Observed in Patients with Advanced Desmoplastic Melanoma

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

Adjuvant Chemoradiation and Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer